The Safety, Tolerability, and Effectiveness of Quetiapine in Postpartum Depression

Last updated: March 4, 2025
Sponsor: Verinder Sharma
Overall Status: Active - Not Recruiting

Phase

1

Condition

Depression (Major/severe)

Depression

Treatment

Quetiapine

Clinical Study ID

NCT04950868
118885
  • Ages 18-45
  • Female

Study Summary

Postpartum depression is a serious disorder that affects approximately 14% of women who have recently given birth. Postpartum depression is either an episode of major depressive disorder (only low periods) or bipolar disorder (periods of lows and highs).

Untreated postpartum depression can negatively affect the mother, the infant and the family. Antidepressants are the most used treatments; however, for many women these drugs are not useful, resulting in a pressing need for effective treatments for postpartum depression. Lack of sleep is common after delivery and can trigger depression in some women. Quetiapine, a drug used for bipolar disorder, major depressive disorder and occasionally sleeplessness has not been well studied in postpartum depression. This study aims to find out how mothers tolerate the drug and whether it is effective for postpartum depression. Results of this study may help investigators carry out a larger study comparing quetiapine and placebo (a sugar pill) in postpartum depression.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Outpatient woman between ages 18 - 45

  • Within 6 months of delivery

  • Have a DSM-5 diagnosis of MDD or BD I, BD II or other specified bipolar or relateddisorder with peripartum onset

  • Have a score of >18 on the 17-item Hamilton Depression Rating Scale (HDRS)

  • Have a score of ≤12 Young Mania Rating Scale (YMRS) at both the screening andbaseline visits

  • Able to communicate in English

  • Capable of providing informed consent

Exclusion

Exclusion Criteria:

  • A diagnosis of schizophrenia spectrum or other psychotic disorders,obsessive-compulsive disorder, eating disorders, substance-related and addictivedisorders

  • At high risk for suicide (actively suicidal or a score of ≥ 3 on item #3 on theHDRS)

  • Receiving a psychotropic drug such a mood stabilizer, an antidepressant or asedative/hypnotic.

  • Receiving psychotherapy

  • Have a physical illness that is a contraindication to the use of quetiapine, or whohave a history of intolerance or nonresponse to quetiapine

  • Pregnant or planning on becoming pregnant during the study

Study Design

Total Participants: 22
Treatment Group(s): 1
Primary Treatment: Quetiapine
Phase: 1
Study Start date:
March 18, 2022
Estimated Completion Date:
June 01, 2025

Connect with a study center

  • Parkwood Institute

    London, Ontario N6C 5J1
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.